Trial · NCT00944710
Outcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Distribution of 10-week Amblyopic-Eye Visual Acuity | 10 weeks after randomization | The primary outcome analysis followed the intent-to-treat principle and included data from 10-week visual acuity exams completed between 8 and 15 weeks (inclusive) with no imputation for missing data. | participants | NUMBER |
| SECONDARY | Treatment Group Comparison of the Proportion of Participants Who Achieved 20/25 or Better Visual Acuity at 10 Weeks Since Randomization | 10 weeks after randomization | The analysis includes data from participants who completed a 10-week exam. | participants | NUMBER |
| SECONDARY | Treatment Group Comparison of the Proportion of Participants Who Have Improved by 2 or More logMAR Visual Acuity Lines at 10 Weeks Since Randomization | 10 weeks after randomization | The analysis included data from 10-week visual acuity exams completed between 8 to 15 weeks (inclusive) according to the principles specified in the primary outcome analysis. | participants | NUMBER |
| SECONDARY | Spectacle Compliance at 10 Weeks by Treatment Group | 10 weeks after randomization | participants | NUMBER | |
| SECONDARY | Average Spectacle Compliance by Treatment Group | 10 weeks after randomization or later (until no further VA improvement, up to maximum of 84 weeks for one subject) | participants | NUMBER | |
| SECONDARY | Atropine Compliance at 10 Weeks by Treatment Group | 10 weeks after randomization | participants | NUMBER | |
| SECONDARY | Average Atropine Compliance by Treatment Group | 10 weeks after randomization or later (until no further VA improvement, up to maximum of 84 weeks for one subject) | participants | NUMBER | |
| PRIMARY | Mean 10-week Amblyopic-Eye Visual Acuity | 10 weeks after randomization | The primary outcome analysis followed the intent-to-treat principle and included data from 10-week visual acuity exams completed between 8 and 15 weeks (inclusive) with no imputation for missing data. | logMAR | MEAN |
| PRIMARY | Distribution of the Change in Amblyopic-Eye Visual Acuity | Randomization to 10 weeks | The primary outcome analysis followed the intent-to-treat principle and included data from 10-week visual acuity exams completed between 8 and 15 weeks (inclusive) with no imputation for missing data. | participants | NUMBER |
| PRIMARY | Mean Change in Amblyopic-Eye Visual Acuity at 10 Weeks From Randomization | Randomization to 10 weeks | The primary outcome analysis followed the intent-to-treat principle and included data from 10-week visual acuity exams completed between 8 and 15 weeks (inclusive) with no imputation for missing data. | logMAR lines | MEAN |
| SECONDARY | Distribution of Interocular Difference at 12-week Exam | 12 weeks after randomization | participants | NUMBER | |
| SECONDARY | Mean Interocular Difference at 12-week Exam | 12 weeks after randomization | logMAR lines | MEAN | |
| SECONDARY | Distribution of 12-week Fellow-Eye Visual Acuity | 12 weeks after randomization | participants | NUMBER | |
| SECONDARY | Mean Fellow-Eye Visual Acuity at 12-week Exam | 12 weeks after randomization | logMAR | MEAN | |
| SECONDARY | Distribution of Change in Fellow-Eye Visual Acuity at 12 Weeks From Randomization | 12 weeks after randomization | participants | NUMBER | |
| SECONDARY | Mean Change in Fellow-Eye Visual Acuity at 12 Weeks From Randomization | 12 weeks after randomization | change in lines | MEAN | |
| SECONDARY | Distribution of Baseline Characteristics at the 10-week Outcome | 10 weeks after randomization | The analysis included participants who completed 10-week exams between 8 and 15 weeks (inclusive) according to the principles specified in the primary outcome analysis. | participants | NUMBER |
| SECONDARY | Mean Amblyopic Eye Visual at Randomization According to Baseline Characteristics for 10-week Outcome | 10 weeks after randomization | The analysis included participants who completed 10-week exams between 8 and 15 weeks (inclusive) according to the principles of the primary outcome analysis. | logMAR | MEAN |
| SECONDARY | Treatment Comparison of Mean Amblyopic Eye Visual Acuity Change at 10-weeks According to Baseline Characteristics | 10 weeks after randomization | The analysis included participants who completed 10-week exams between 8 and 15 weeks (inclusive) according to the principles of the primary outcome analysis. | logMAR lines | MEAN |
| SECONDARY | Distribution of Amblyopic-Eye Visual Acuity at Best Outcome Visit | 10 weeks after randomization or later (until no further VA improvement, up to maximum of 84 weeks for one subject) | The analysis includes data from participants who completed the 10-week exam and/or a later visit. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00944710/outcomes